Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

I5771

Sigma-Aldrich

Interleukin-6 Receptor Soluble Fragment human

recombinant, expressed in Sf21 cells, ≥97% (SDS-PAGE), lyophilized powder

Synonyme(s) :

IL-6 sR

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Sélectionner une taille de conditionnement

25 μG
936,00 €

936,00 €


Date d'expédition estimée le16 avril 2025



Sélectionner une taille de conditionnement

Changer de vue
25 μG
936,00 €

About This Item

Numéro MDL:
Code UNSPSC :
51111800
Nomenclature NACRES :
NA.41

936,00 €


Date d'expédition estimée le16 avril 2025


Produit recombinant

expressed in Sf21 cells

Niveau de qualité

Essai

≥97% (SDS-PAGE)

Forme

lyophilized powder

Impuretés

endotoxin, tested

Température de stockage

−20°C

Catégories apparentées

Description générale

Interleukin-6 is a pleotropic cytokine involved in hematopoiesis, inflammation and immune response. IL-6 is secreted by macrophages, dendritic cells and B cells, in response to TNF-α, PGDF and IL-1. The signaling by IL-6 is mediated by heterodimeric receptor, IL-6R, comprising of IL-6Rα (soluble factor) and gp130 (sometimes called IL-6Rβ). Gp130 is crucial component for downstream signal transduction. In response to IL-6, gp130 activates kinases of JAK family, STATs, MAPK and Ras proteins. [1][2][3] IL-6R-mediated signaling is essential for normal development of T and B cells [4] and has been implicated in many diseases such as rheumatoid arthritis, Crohn disease, sepsis, fever, systemic lupus erythematosus, osteoporosis and insulin resistance[2][5][6][7]
Interleukin-6 Receptor soluble fragment specifically binds and inhibits the activity of human IL-6 in free form or when bound to cell surface receptors.

Application

Interleukin-6 Receptor soluble fragment elicits a 50% increase in IL-6 activity in cell based assay at a concentration (EC50) of 1-10 ng/ml.

Forme physique

Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing 1.25 mg bovine serum albumin.

Remarque sur l'analyse

The receptor mediated activity of human IL-6 receptor soluble fragment is measured by its ability to increase the IL-6 inhibition of M1 cells.[8]

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves, type N95 (US)


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

T Gustot et al.
Gut, 54(4), 488-495 (2005-03-09)
Soluble cytokine receptors (sCRs) modulate the in vivo activity of cytokines. Deficient sCR production could participate in the pathogenesis and course of Crohn's disease (CD). The aim of the study was to examine the profile of sCRs in CD patients
Interleukin-6-type cytokines.
P B Sehgal et al.
Annals of the New York Academy of Sciences, 762, 1-14 (1995-07-21)
David S Hong et al.
Cancer, 110(9), 1911-1928 (2007-09-13)
Interleukin-6 (IL-6) plays a major role in the response to injury or infection and is involved in the immune response, inflammation, and hematopoiesis. Its deregulation impacts numerous disease states, including many types of cancer. Consequently, modulating IL-6 may be an
T van der Poll et al.
Infectious disease clinics of North America, 13(2), 413-426 (1999-05-26)
Clinical trials with anti-inflammatory agents in patients with sepsis are based on the assumption that excessive proinflammatory activity of the cytokine network negatively influences the outcome of severe bacterial infections. The failure of these trials to show clinical benefit, in
Oliver Dienz et al.
Clinical immunology (Orlando, Fla.), 130(1), 27-33 (2008-10-11)
Cytokines have long been known to profoundly influence the adaptive immune response by determining CD4 T cell differentiation. Although IL-6 has been initially characterized as a B cell growth factor and inducer of antibody production research from our lab and

Questions

Évaluations

Aucune valeur de notation

Filtres actifs

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique